Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
Trends Mol Med. 2009 Nov;15(11):531-41. doi: 10.1016/j.molmed.2009.09.005. Epub 2009 Oct 12.
The interplay between p53 and apoptosis in diseases such as cancer, neurodegeneration, ischemia and atherosclerosis underscores the need to understand the complexity of p53 networks. Here, we highlight recent studies of p53-induced apoptosis in human diseases, with a focus on the modulation of liver cell apoptosis. In addition, recent work has provided new insights into mechanisms underlying the antiapoptotic functions of the endogenous bile acid ursodeoxycholic acid (UDCA), suggesting that the finely tuned, complex control of p53 by Mdm2 is a key step in the UDCA modulation of deregulated, p53-triggered apoptosis. The effect of targeting cell death signaling proteins has been established in preclinical models of human diseases. Finally, we review recent therapeutic strategies and clinical applications of targeted agents, with a particular emphasis on the potential use of UDCA.
p53 与细胞凋亡在癌症、神经退行性疾病、缺血和动脉粥样硬化等疾病中的相互作用强调了需要理解 p53 网络的复杂性。在这里,我们重点介绍了 p53 诱导的人类疾病细胞凋亡的最新研究,特别关注肝细胞凋亡的调控。此外,最近的研究工作为内源性胆汁酸熊去氧胆酸 (UDCA) 的抗细胞凋亡功能的机制提供了新的见解,表明 Mdm2 对 p53 的精细调控是 UDCA 调节失调的、p53 触发的细胞凋亡的关键步骤。靶向细胞死亡信号蛋白的效果已在人类疾病的临床前模型中得到证实。最后,我们回顾了针对这些细胞死亡信号蛋白的治疗策略和临床应用的最新进展,特别强调了 UDCA 的潜在用途。